NEW YORK, July 29 -- Abbott Laboratories and Dharmacon, of Lafayette, Colo., today announced a collaboration to develop a library of short-interfering RNA (siRNA) covering 4,000 genes to identify potential drug targets for therapeutics.
Financial details were not disclosed.
The siRNA library will be used in functional genomic studies designed to identify and validate drug targets for therapeutics for cancer, diabetes, pain management, inflammation, and neurological disorders.